Colorectal cancer (CRC) is a significant and growing health burden in Hong Kong. According to data from Hong Kong Cancer Registry, CRC ranked the first in incidence and the second in mortality, with around 5,000 new cases diagnosed and more than 2,000 cancer-related mortality in 2014. The investigators aim to evaluate the association between serial weight change during first line treatment and outcomes in patients with metastatic CRC.
Studies have suggested that exposure to a greater number of chemotherapeutic agents is associated with better survival in metastatic colorectal cancer. Multiple factors might affect body weight during treatment. Cancer-related symptoms can impair quality of life and appetite. Cachexia syndrome affects around 50% of colon cancer patients and is characterized by cancer-induced catabolism with involuntary weight loss (fat and muscle), patients have increased lipolysis and change in skeletal muscle metabolism, including increased energy expenditure at rest and protein degradation, and decreased protein synthesis. Besides these disease factors, treatment related side effects are common causes of weight loss, such as inability to ingest or digest food effectively due to nausea, vomiting, and malaise. Based on these factors and the hypotheses between tumour control and weight gain, monitoring the serial weight change can have practical value.
Study Type
OBSERVATIONAL
Enrollment
264
systemic chemotherapy (capecitabine or fluorouracil, oxaliplatin or irinotecan, with or without biological agents including cetuximab, bevacizumab, or panitumumab.
Department of Clinical Oncology, Tuen Mun Hospital, Tuen Mun
Hong Kong, Hong Kong
RECRUITINGProgression-free survival
Survival time from start of anti-cancer treatment until disease progression, or death from disease, or loss of follow-up
Time frame: From date of start of anti-cancer treatment until the date of first documented progression (assessed by physical examination, imaging, or blood biomarkers) or date of death from any cause, whichever came first, assessed up to 60 months
Overall survival
Survival time from start of anti-cancer treatment until death from any cause, or loss of follow-up
Time frame: From date of start of anti-cancer treatment until the date of death from any cause (assessed by physical examination, imaging, or blood biomarkers), assessed up to 60 months
Chemotherapy dose change
Chemotherapy dose change (in percentage change)
Time frame: from start of first-line anti-cancer treatment until completion, assessed by clinical assessment up to 60 months
Chemotherapy interruption
Chemotherapy dose interruption (in percentage change)
Time frame: from start of first-line anti-cancer treatment until completion, assessed by clinical assessment up to 60 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.